These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

206 related items for PubMed ID: 29330579

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Nivolumab-induced aplastic anemia: A case report and literature review.
    Comito RR, Badu LA, Forcello N.
    J Oncol Pharm Pract; 2019 Jan; 25(1):221-225. PubMed ID: 28825374
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Spontaneous hematoma of the thigh associated with antiproteinase-3 antibody in a patient with metastatic squamous cell carcinoma treated with nivolumab.
    Keung YK, Hu EH.
    J Oncol Pharm Pract; 2019 Jul; 25(5):1261-1264. PubMed ID: 29984627
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Immune-related intestinal pseudo-obstruction associated with nivolumab treatment in a lung cancer patient.
    Fragulidis G, Pantiora E, Michalaki V, Kontis E, Primetis E, Vezakis A, Polydorou A.
    J Oncol Pharm Pract; 2019 Mar; 25(2):487-491. PubMed ID: 29067858
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Severe Exacerbation of Myasthenia Gravis Associated with Checkpoint Inhibitor Immunotherapy.
    Cooper DS, Meriggioli MN, Bonomi PD, Malik R.
    J Neuromuscul Dis; 2017 Mar; 4(2):169-173. PubMed ID: 28505981
    [Abstract] [Full Text] [Related]

  • 12. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM, Freeman GJ, McDermott DF.
    Clin Ther; 2015 Apr 01; 37(4):764-82. PubMed ID: 25823918
    [Abstract] [Full Text] [Related]

  • 13. Nivolumab-induced hepatitis: A rare side effect of an immune check point inhibitor.
    Mathew Thomas V, Bindal P, Ann Alexander S, McDonald K.
    J Oncol Pharm Pract; 2020 Mar 01; 26(2):459-461. PubMed ID: 30909794
    [Abstract] [Full Text] [Related]

  • 14. Immune checkpoint inhibitor (nivolumab)-associated kidney injury and the importance of recognizing concomitant medications known to cause acute tubulointerstitial nephritis: a case report.
    Koda R, Watanabe H, Tsuchida M, Iino N, Suzuki K, Hasegawa G, Imai N, Narita I.
    BMC Nephrol; 2018 Feb 27; 19(1):48. PubMed ID: 29486725
    [Abstract] [Full Text] [Related]

  • 15. The Analysis of Renal Infiltrating Cells in Acute Tubulointerstitial Nephritis Induced by Anti-PD-1 Antibodies: A Case Report and Review of the Literature.
    Tabei A, Watanabe M, Ikeuchi H, Nakasatomi M, Sakairi T, Kaneko Y, Maeshima A, Kaira K, Hirato J, Nojima Y, Hiromura K.
    Intern Med; 2018 Nov 01; 57(21):3135-3139. PubMed ID: 29877267
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Complete response upon salvage chemotherapy after anti-PD1 failure: Watch and wait.
    Saleh K, Bellanger C, Garcia G, Classe M, Even C.
    Eur J Cancer; 2021 Mar 01; 145():155-157. PubMed ID: 33476895
    [No Abstract] [Full Text] [Related]

  • 20. Nivolumab for the treatment of Japanese patients with advanced metastatic non-small cell lung cancer: a review of clinical trial evidence for efficacy and safety.
    Hida T.
    Ther Adv Respir Dis; 2018 Mar 01; 12():1753466618801167. PubMed ID: 30249170
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.